Tesolato Sofía, Vicente-Valor Juan, Paz-Cabezas Mateo, Gómez-Garre Dulcenombre, Sánchez-González Silvia, Ortega-Hernández Adriana, de la Serna Sofía, Domínguez-Serrano Inmaculada, Dziakova Jana, Rivera Daniel, Jarabo Jose-Ramón, Gómez-Martínez Ana-María, Hernando Florentino, Torres Antonio, Iniesta Pilar
Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University, 28040 Madrid, Spain.
San Carlos Health Research Institute (IdISSC), 28040 Madrid, Spain.
Biomedicines. 2024 Mar 21;12(3):703. doi: 10.3390/biomedicines12030703.
The application of bacterial metagenomic analysis as a biomarker for cancer detection is emerging. Our aim was to discover gut microbiota signatures with potential utility in the diagnosis of colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). A prospective study was performed on a total of 77 fecal samples from CRC and NSCLC patients and controls. DNA from stool was analyzed for bacterial genomic sequencing using the Ion Torrent™ technology. Bioinformatic analysis was performed using the QIIME2 pipeline. We applied logistic regression to adjust for differences attributable to sex, age, and body mass index, and the diagnostic accuracy of our gut signatures was compared with other previously published results. The feces of patients affected by different tumor types, such as CRC and NSCLC, showed a differential intestinal microbiota profile. After adjusting for confounders, (OR = 53.3), (OR = 6.01), (OR = 5.35), (OR = 9.42), (OR = 6.72), (OR = 5.44), and (OR = 78.9) remained significantly associated with the risk of CRC. Two genera from the family, (OR = 20.1) and an uncharacterized genus (OR = 160.1), were associated with the risk of NSCLC. Our two panels had better diagnostic capacity for CRC (AUC = 0.840) and NSLC (AUC = 0.747) compared to the application of two other published panels to our population. Thus, we propose a gut bacteria panel for each cancer type and show its potential application in cancer diagnosis.
细菌宏基因组分析作为癌症检测生物标志物的应用正在兴起。我们的目的是发现肠道微生物群特征，其在结直肠癌（CRC）和非小细胞肺癌（NSCLC）诊断中具有潜在应用价值。对来自CRC和NSCLC患者及对照的总共77份粪便样本进行了一项前瞻性研究。使用Ion Torrent™技术对粪便中的DNA进行细菌基因组测序分析。使用QIIME2管道进行生物信息学分析。我们应用逻辑回归来调整因性别、年龄和体重指数导致的差异，并将我们的肠道特征诊断准确性与其他先前发表的结果进行比较。受不同肿瘤类型（如CRC和NSCLC）影响的患者粪便显示出不同的肠道微生物群特征。在调整混杂因素后， （比值比=53.3）、 （比值比=6.01）、 （比值比=5.35）、 （比值比=9.42）、 （比值比=6.72）、 （比值比=5.44）和 （比值比=78.9）仍与CRC风险显著相关。来自 科的两个属， （比值比=20.1）和一个未鉴定的属（比值比=160.1）与NSCLC风险相关。与将其他两个已发表的检测组合应用于我们的人群相比，我们的两个检测组合对CRC（曲线下面积=0.840）和NSLC（曲线下面积=0.747）具有更好的诊断能力。因此，我们针对每种癌症类型提出了一个肠道细菌检测组合，并展示了其在癌症诊断中的潜在应用。
